Log In
Print
BCIQ
Print
Print this Print this
 

nesvacumab (REGN910, SAR307746)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionAntibody against angiopoietin 2 (ANG2; ANGPT2)
Molecular Target Angiopoietin 2 (ANG2) (ANGPT2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today